JP2010532765A5 - - Google Patents

Download PDF

Info

Publication number
JP2010532765A5
JP2010532765A5 JP2010515319A JP2010515319A JP2010532765A5 JP 2010532765 A5 JP2010532765 A5 JP 2010532765A5 JP 2010515319 A JP2010515319 A JP 2010515319A JP 2010515319 A JP2010515319 A JP 2010515319A JP 2010532765 A5 JP2010532765 A5 JP 2010532765A5
Authority
JP
Japan
Prior art keywords
inhibitor
pharmaceutical composition
treatment
biofilm
development
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010515319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010532765A (ja
JP5476297B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2008/001017 external-priority patent/WO2009006699A1/en
Publication of JP2010532765A publication Critical patent/JP2010532765A/ja
Publication of JP2010532765A5 publication Critical patent/JP2010532765A5/ja
Application granted granted Critical
Publication of JP5476297B2 publication Critical patent/JP5476297B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010515319A 2007-07-12 2008-07-11 バイオフィルム治療 Expired - Fee Related JP5476297B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2007903788A AU2007903788A0 (en) 2007-07-12 Biofilm treatment
AU2007903788 2007-07-12
PCT/AU2008/001017 WO2009006699A1 (en) 2007-07-12 2008-07-11 Biofilm treatment

Publications (3)

Publication Number Publication Date
JP2010532765A JP2010532765A (ja) 2010-10-14
JP2010532765A5 true JP2010532765A5 (enExample) 2011-08-25
JP5476297B2 JP5476297B2 (ja) 2014-04-23

Family

ID=40228120

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010515319A Expired - Fee Related JP5476297B2 (ja) 2007-07-12 2008-07-11 バイオフィルム治療

Country Status (13)

Country Link
US (2) US8241611B2 (enExample)
EP (2) EP2175851B1 (enExample)
JP (1) JP5476297B2 (enExample)
KR (2) KR101614938B1 (enExample)
CN (2) CN101842097B (enExample)
AU (1) AU2008274906B2 (enExample)
CA (1) CA2693695C (enExample)
DK (1) DK2175851T3 (enExample)
ES (2) ES2432690T3 (enExample)
NZ (2) NZ595252A (enExample)
PL (1) PL2175851T3 (enExample)
SG (1) SG183016A1 (enExample)
WO (1) WO2009006699A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
US8129500B2 (en) * 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
US20100092471A1 (en) 2006-06-27 2010-04-15 Oral Health Australia Pty Ltd Porphyromonas Gingivalis Polypeptides Useful in the Prevention of Periodontal Disease
NZ595252A (en) 2007-07-12 2013-11-29 Oral Health Australia Pty Ltd Biofilm treatment
NZ605037A (en) 2007-07-12 2014-05-30 Oral Health Australia Pty Ltd Immunology treatment for biofilms
DK2328914T3 (en) 2008-08-29 2017-07-10 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of P. gingivalis infection
TWI391148B (zh) * 2009-04-01 2013-04-01 Colgate Palmolive Co 含有生物可接受性及生物活性之玻璃的非水性牙膏組成物及其使用與製造之方法
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
KR101352795B1 (ko) * 2010-02-26 2014-02-17 주식회사 나이벡 치아의 접합능을 향상시키기 위한 치과용 클린저 조성물
MY162557A (en) 2010-02-26 2017-06-15 Oral Health Australia Pty Ltd Treatment or prevention of infection
WO2012027690A1 (en) * 2010-08-27 2012-03-01 The Regents Of The University Of Michigan Control of biofilm formation
US9549904B2 (en) 2012-06-06 2017-01-24 Thomas Bryan Method of destroying bacterial biofilm using sterile intravenous or intracavernous glycerin
US9480669B2 (en) 2015-01-06 2016-11-01 The Regents Of The University Of California Method of destroying and preventing bacterial and fungal biofilm by amino acid infusion
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US9795809B2 (en) 2013-12-23 2017-10-24 Embro Corporation Use of moss to improve dental health
WO2017011588A1 (en) 2015-07-14 2017-01-19 Research Institute At Nationwide Children's Hospital Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
EP3328429B1 (en) 2015-07-31 2025-07-16 The Research Institute at Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
US11564982B2 (en) 2017-01-04 2023-01-31 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
CA3049114A1 (en) 2017-01-04 2018-07-12 Lauren O. Bakaletz Antibody fragments for the treatment of biofilm-related disorders
US11382885B2 (en) 2017-06-07 2022-07-12 The Regents Of The University Of California Compositions for treating fungal and bacterial biofilms and methods of using the same
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US12365710B2 (en) 2018-10-05 2025-07-22 Research Institute At Nationwide Children's Hospital HMGB1 protein derivatives for the removal of biofilms
US12226386B2 (en) 2018-12-03 2025-02-18 The Regents Of The University Of California Compositions and methods for treating biofilms
US12109176B1 (en) 2023-04-20 2024-10-08 Thomas Bryan Effect of glycerol on biofilm forming bacteria and fungi that changes the microbes sensitivity to pro and anti-biofilm non-toxic, non-bonded plasma amino acids and amino acid derivatives

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210035A (en) * 1980-05-19 1993-05-11 Board Of Trustees Of Leland Stanford Jr. University Non-reventing live vaccines
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5830710A (en) 1988-09-08 1998-11-03 University Of Florida Cloned porphyromonas gingivalis genes and probes for the detection of periodontal disease
WO1994027606A1 (en) * 1993-05-28 1994-12-08 Unisearch Limited Method of treating helicobacter pylori infection
US5711937A (en) * 1993-06-28 1998-01-27 Lion Corporation Oral composition
US6017532A (en) * 1993-09-10 2000-01-25 University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase
US5523390A (en) * 1993-09-10 1996-06-04 University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase
US5475097A (en) * 1993-10-21 1995-12-12 University Of Georgia Research Foundation, Inc. Lysine-specific Porphyromonas gingivalis proteinase
WO1995007286A1 (en) 1993-09-10 1995-03-16 University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase coding sequences
JPH0797395A (ja) 1993-09-28 1995-04-11 Kyowa Medex Co Ltd ポルフイロモナス・ジンジバリス線毛蛋白質の配列を含有するペプチド類及びその用途
US5948636A (en) 1994-03-29 1999-09-07 Kyowa Hakko Kogyo Co., Ltd. DNA and host cells encoding a cell surface protein of porphyromonas gingivalis
AUPN627595A0 (en) * 1995-10-30 1995-11-23 University Of Melbourne, The Diagnostics and treatments of periodontal disease
EP0888124A4 (en) 1996-03-22 2001-04-11 Univ Georgia Res Found Immunogenic assemblies of Porphyromonas Gingivalis peptides and their methods
AUPN901296A0 (en) * 1996-03-29 1996-04-26 University Of Melbourne, The Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
US7341727B1 (en) * 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AUPO652897A0 (en) * 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
US8129500B2 (en) * 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
AUPP083997A0 (en) * 1997-12-10 1998-01-08 Csl Limited Porphyromonas gingivalis nucleotides
KR100603552B1 (ko) 1997-12-10 2006-07-20 씨에스엘 리미티드 포피로모나스 긴기발리스 폴리펩티드 및 뉴클레오티드
US6444799B1 (en) * 1997-12-31 2002-09-03 Csl Limited P. gingivalis polynucleotides and uses thereof
AUPP893999A0 (en) * 1999-03-01 1999-03-25 Csl Limited Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with porphyromonas gingivalis
JP2003534235A (ja) 1999-05-12 2003-11-18 ザ ゼネラル ホスピタル コーポレーション バイオフイルムの透過性化
GB9913437D0 (en) 1999-06-09 1999-08-11 Medical Res Council Fusion proteins
AUPQ485999A0 (en) * 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
AUPQ718200A0 (en) * 2000-04-28 2000-05-25 Csl Limited Porphyromonas gingivalis recombinant proteins and truncations
US6576226B1 (en) * 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US6726898B2 (en) * 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US20030083287A1 (en) * 2000-11-30 2003-05-01 Burgess Nicola A. ginS
AUPR575401A0 (en) 2001-06-18 2001-07-12 Unisearch Limited Method of causing sloughing
GB2381449A (en) * 2001-10-31 2003-05-07 Smithkline Beecham Plc Oral hygiene compositions comprising an electron acceptor
JP2003192616A (ja) 2001-12-27 2003-07-09 Univ Nihon 歯周病用dnaワクチン
JP2003286191A (ja) 2002-03-27 2003-10-07 Univ Nihon 歯周病用粘膜免疫ワクチン
JPWO2004083425A1 (ja) * 2003-03-17 2006-06-22 麒麟麦酒株式会社 歯周病治療剤
CA2535799A1 (en) * 2003-08-15 2005-03-03 University Of Florida Identification of porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases
KR101178776B1 (ko) * 2004-02-06 2012-09-07 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 치료학적 잠재성을 가진 어드헤신 및 어드헤신계 단백질을 동정하기 위한 컴퓨터 장치
US20070098649A1 (en) * 2004-03-22 2007-05-03 The Board Of Trustees Of The University Of Illinois Method and composition for controlling oral pathogens
EP1799705A4 (en) * 2004-09-23 2008-11-05 Univ Melbourne Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection
WO2008016385A2 (en) 2006-01-20 2008-02-07 The University Of Washington Deacylase polypeptides, deacylase polynucleotides, and methods of use thereof
US20100092471A1 (en) * 2006-06-27 2010-04-15 Oral Health Australia Pty Ltd Porphyromonas Gingivalis Polypeptides Useful in the Prevention of Periodontal Disease
WO2008124646A2 (en) 2007-04-06 2008-10-16 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Use of amyloid proteins as vaccine scaffolds
NZ595252A (en) 2007-07-12 2013-11-29 Oral Health Australia Pty Ltd Biofilm treatment
NZ605037A (en) * 2007-07-12 2014-05-30 Oral Health Australia Pty Ltd Immunology treatment for biofilms
DK2328914T3 (en) 2008-08-29 2017-07-10 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of P. gingivalis infection
WO2010144968A1 (en) * 2009-06-19 2010-12-23 Oral Health Australia Pty Ltd Casein derived protease inhibitory peptides

Similar Documents

Publication Publication Date Title
JP2010532765A5 (enExample)
EP2638905A3 (en) Biofilm treatment
JP2009531457A5 (enExample)
UA90521C2 (uk) Фармацевтична композиція, що містить симвастатин і езетиміб
MX2011013201A (es) Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion.
NZ593823A (en) Compositions and methods for the treatment or the prevention of infections by e. coli
MX2010014041A (es) Una forma cristalina de posaconazol.
GEP20115302B (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5- trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
EP2607348A3 (en) Plasminogen Activator Inhibitor-1 Inhibitor
ATE520668T1 (de) Sigmarezeptor-inhibitoren
WO2007143557A3 (en) Compounds and methods for treating mammalian gastrointestinal parasitic infections
WO2011049327A3 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
ATE516035T1 (de) Fixdosisassoziation von phytat und zink
JP2005047896A5 (enExample)
EA200500672A1 (ru) Содержащие альфузозин композиции с отсроченным высвобождением
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
WO2019004788A3 (ko) 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물
IN2013CN00089A (enExample)
NZ592567A (en) Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-iv, and other antidiabetic or antiobesity agents as active ingredients
PH12012502198A1 (en) Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof
MY162654A (en) Pharmaceutical composition for treating cutaneous burns
WO2007138233A3 (fr) Utilisation du zatosetron pour le traitement de la rosacee
WO2009041026A1 (ja) Cxcl10産生抑制剤
EA200802262A1 (ru) Назальные и буккальные композиции для борьбы с храпом